AEON Biopharma, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-09. 3 holders' latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Daewoong Co.,Ltd. ("DWC") | 49.99% | 12,009,737 | SCHEDULE 13D, 2026-01-29 | 2026-01-21 |
| Timothy P. Lynch | 13% | 6,500,000 | SCHEDULE 13G, 2026-08-21 | 2026-08-19 |
| Stonepine Capital Management, LLC | 9.9% | 6,892,682 | SCHEDULE 13G, 2026-07-21 | 2026-07-15 |
| Alta Partners LLC | 2.1% | 249,870 | SCHEDULE 13G/A, 2025-10-14 | 2025-09-30 |
Purpose of Transaction (Item 4)
Daewoong Co.,Ltd. ("DWC")
The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. DWC is a shareholder of DWP with 52% of shares outstanding. DWP is the counterparty to the Issuer's license agreements for License & Supply Agreement, effective as of December 20, 2019, as amended, with DWP to provide the Issuer exclusive rights to commercialize and distribute ABP-450 in certain territories. Our future success currently depends entirely on the successful and timely regulatory approval and commercialization of the Issuer's only product candidate, ABP-450. The Issuer plans to develop ABP-450 to address the estimated $3.0 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by DWP, in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the FDA, Health Canada and EMA. The purpose of transaction is part of the Reporting Persons' efforts to strengthen the partnership with the Issuer, whose goal is to achieve development of ABP-450, for which the parties have previously worked together to gain certain approvals from the U.S. Food and Drug Administration (FDA). The Reporting Persons intend to review its investment in the Issuer on an ongoing basis, and currently have no intent to sell, transfer or otherwise …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-29; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-09 | Alta Partners LLC | 5.1% | SCHEDULE 13G/A |
| 2025-10-14 | Alta Partners LLC | 2.1% | SCHEDULE 13G/A |
| 2026-01-29 | Daewoong Co.,Ltd. ("DWC") | 0.9% | SCHEDULE 13D/A |
| 2026-01-29 | Daewoong Co.,Ltd. ("DWC") | 49.99% | SCHEDULE 13D |
| 2026-07-21 | Stonepine Capital Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-08-21 | Timothy P. Lynch | 13% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for AEON Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.